Related Experiment Video
Updated: Apr 6, 2026
10:03
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
973
Evolving targeted therapies for right ventricular failure
1Vanderbilt University Medical Center and School of Medicine, Vanderbilt Heat and Vascular Institute , Nashville, TN , USA +1 615 294 5437 ; +1 615 343 4841 ; Thomas.g.disalvo@vanderbilt.edu.
Expert Opinion on Biological Therapy
|August 4, 2015
Summary
Exploring novel therapies for right ventricular failure, this review highlights emerging pharmacologic agents and future regenerative strategies. These approaches aim to address the unique challenges of right ventricular regeneration, offering new hope for patients.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Molecular Cardiology
Background:
- Right and left ventricles exhibit distinct embryological origins, morphology, and cardiodynamics.
- The concept of targeted therapies specifically for the right ventricle remains a subject of debate.
Purpose of the Study:
- To review current and future therapeutic strategies for right ventricular failure.
- To explore regenerative approaches for the right ventricle.
Main Methods:
- Focuses on evolving pharmacologic agents for right ventricular failure.
- Examines future therapeutic avenues including epigenetic modulation, gene therapy, cell regeneration, and cardiac tissue engineering.
Main Results:
- Current pharmacologic agents include metabolic modulators and phosphodiesterase type V inhibitors.
- Future strategies involve epigenetic modulation (miRNAs, lncRNAs), genomic editing, cell-based regeneration, and tissue engineering.
Conclusions:
- Right ventricular regeneration necessitates a holistic approach distinct from left ventricular failure strategies.
- Promising methods include in vivo fibroblast reprogramming into cardiomyocytes and targeted gene editing for genetic myocardial diseases.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
585
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
585
01:30Cardiomyopathy II: Dilated Cardiomyopathy
772
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
772
01:30Heart Failure V: Medical Management
546
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
546
01:29Cardiomyopathy V: Interprofessional Care
661
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
661
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
607
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
607